AbbVie Inc (ABBV)

64.45
NYSE : Health Care
Prev Close 64.45
Day Low/High 0.00 / 0.00
52 Wk Low/High 45.45 / 71.51
Avg Volume 9.21M
Exchange NYSE
Shares Outstanding 1.62B
Market Cap 104.03B
EPS 3.20
P/E Ratio 19.32
Div & Yield 2.28 (3.50%)

Latest News

AbbVie And Bristol-Myers Squibb Announce Oncology Clinical Collaboration To Evaluate The Combination Of Rova-T Plus Opdivo And Opdivo + Yervoy Regimen

AbbVie And Bristol-Myers Squibb Announce Oncology Clinical Collaboration To Evaluate The Combination Of Rova-T Plus Opdivo And Opdivo + Yervoy Regimen

- Collaboration will explore the safety and potential enhanced efficacy of combining checkpoint inhibitors with a cancer stem cell-targeting antibody drug conjugate in SCLC

AbbVie And Bristol-Myers Squibb Announce Oncology Clinical Collaboration To Evaluate The Combination Of Rova-T Plus Opdivo And Opdivo + Yervoy Regimen

AbbVie And Bristol-Myers Squibb Announce Oncology Clinical Collaboration To Evaluate The Combination Of Rova-T Plus Opdivo And Opdivo + Yervoy Regimen

AbbVie (NYSE:ABBV) and Bristol-Myers Squibb Company (NYSE:BMY) today announced a clinical trial collaboration to evaluate the safety, tolerability and efficacy of AbbVie's investigational biomarker-specific antibody...

CHMP Grants Positive Opinion For Shorter Treatment Duration With AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) For Patients With Genotype 4 Chronic Hepatitis C With Compensated Cirrhosis (Child-Pugh A)

CHMP Grants Positive Opinion For Shorter Treatment Duration With AbbVie's VIEKIRAX® (ombitasvir/paritaprevir/ritonavir Tablets) For Patients With Genotype 4 Chronic Hepatitis C With Compensated Cirrhosis (Child-Pugh A)

- The CHMP opinion represents a positive advance toward approval of the 12-week regimen of VIEKIRAX with ribavirin for genotype 4 (GT4) chronic hepatitis C virus (HCV) infected adult patients with or without compensated cirrhosis

Do the Math! Stocks Are Poised for a Fall

Do the Math! Stocks Are Poised for a Fall

Optimism is warranted over the long haul, but investors probably face a short-term headache. Here are the crucial numbers and events to watch in the week ahead.

Week Ahead: Fed's July Meeting Overshadows Another Busy Earnings Week

Week Ahead: Fed's July Meeting Overshadows Another Busy Earnings Week

The Federal Reserve will steal focus from another onslaught of earnings in the coming week as investors remain wary over the central bank's rate-hike timetable.

3 Stocks Driving The Drugs Industry Higher

3 Stocks Driving The Drugs Industry Higher

TheStreet highlights 3 stocks pushing the drugs industry higher today.

Why Nasdaq-Traded Marijuana Stocks Remain Undervalued

Why Nasdaq-Traded Marijuana Stocks Remain Undervalued

Nasdaq-traded marijuana stocks are undervalued as investors remain skittish and the use of drugs produced by these biopharmaceutical companies have not been widely adopted.

3 Stocks Pulling The Health Care Sector Downward

3 Stocks Pulling The Health Care Sector Downward

TheStreet highlights 3 stocks pushing the health care sector lower today.

Could the Dow Jump Up Another 400 Points by Year-End?

Could the Dow Jump Up Another 400 Points by Year-End?

Concerns that the market is overvalued continue to arise as the S&P 500 has increased by 7.6% during the past two weeks. But there may still be room for growth.

AbbVie Payout Reminder; Buy Today

Don't miss strong performer ABBV's $0.57 dividend.

Shire’s Shares Rise on FDA Approval of Dry Eye Med

Shire’s Shares Rise on FDA Approval of Dry Eye Med

Jefferies estimates Xiidra could yield revenue of $1.5 billion within five years of its launch.

AbbVie Presents Initial Data From Pivotal Phase-3 Trial Evaluating The Efficacy And Safety Of HUMIRA® (adalimumab) For Moderate To Severe Fingernail Psoriasis In Adult Patients At Psoriasis 2016 Congress

AbbVie Presents Initial Data From Pivotal Phase-3 Trial Evaluating The Efficacy And Safety Of HUMIRA® (adalimumab) For Moderate To Severe Fingernail Psoriasis In Adult Patients At Psoriasis 2016 Congress

- Data from Phase 3 randomized, placebo controlled trial demonstrates that 46.6 percent of adult patients with moderate to severe psoriasis treated with HUMIRA® achieved at least a 75 percent improvement in their moderate to severe fingernail psoriasis

AbbVie Is Poised to Move Even Higher

AbbVie Is Poised to Move Even Higher

With solid footing developing underneath and room to run on the upside, AbbVie is setting up well for a fresh rally.

Take Stock of Your High-Dividend Stocks

Valuations are stretched in certain names and industries, so some profit-taking appears in order.

Take Stock of Your High-Dividend Stocks

Valuations are stretched in certain names and industries, so some profit-taking appears in order.

Biogen And AbbVie's Once-Monthly ZINBRYTA™ (Daclizumab) Approved In European Union For Treatment Of Multiple Sclerosis

Biogen And AbbVie's Once-Monthly ZINBRYTA™ (Daclizumab) Approved In European Union For Treatment Of Multiple Sclerosis

The European Commission (EC) has granted marketing authorization for ZINBRYTA™ (daclizumab) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), Biogen (NASDAQ: BIIB) and AbbVie...

Picking Up More Orasure

A terminated co-promotion sent shares lower, so we'll use this as a buying opportunity.

AbbVie's HUMIRA® (adalimumab) Receives U.S. Food And Drug Administration Approval To Treat Adults With Non-Infectious Intermediate, Posterior And Panuveitis

AbbVie's HUMIRA® (adalimumab) Receives U.S. Food And Drug Administration Approval To Treat Adults With Non-Infectious Intermediate, Posterior And Panuveitis

- Non-infectious uveitis is an immune-mediated disease that can flare and impair vision

Company Updates and Dividend Reminder

It's the last day of the quarter; earnings season is around the corner.

16 Biopharma Companies Besides Medivation That Are Attractive Targets

16 Biopharma Companies Besides Medivation That Are Attractive Targets

Besides Sanofi, Biogen is the next most likely to complete a sizable transaction in the next 12 months, according to Credit Suisse analysts.

8 Beaten-Down Post-Brexit Bargains

These names are now oversold and are sitting at attractive prices.

AbbVie Announces Fourth Breakthrough Therapy Designation Granted By The U.S. Food And Drug Administration (FDA) For Ibrutinib (IMBRUVICA®) For Chronic Graft-Versus-Host-Disease (cGVHD), A Rare Condition With Limited Treatment Options

AbbVie Announces Fourth Breakthrough Therapy Designation Granted By The U.S. Food And Drug Administration (FDA) For Ibrutinib (IMBRUVICA®) For Chronic Graft-Versus-Host-Disease (cGVHD), A Rare Condition With Limited Treatment Options

- FDA also granted ibrutinib Orphan Drug Designation for this condition. There are currently no therapies specifically approved for cGVHD, a severe and potentially life-threatening condition in which transplanted cells from donor attack the patient's body

Assessing Portfolio's Europe/U.K. Exposure

As Brexit vote approaches, we would view near-term weakness as an opportunity to put new money to work.

AbbVie Teams Up With Leading Nonprofit Organizations To Give Back To Underserved Local Communities

AbbVie Teams Up With Leading Nonprofit Organizations To Give Back To Underserved Local Communities

- The third annual "Week of Possibilities" will engage 5,500 AbbVie employees in more than 50 countries to volunteer more than 25,000 hours in hands-on service projects in the communities where they live and work

AbbVie Declares Quarterly Dividend

AbbVie Declares Quarterly Dividend

Market Slide Creates Opportunities

There's room to add to the portfolio.